(MedPage Today) — The FDA has approved a new sublingual tablet formulation of the opioid addiction drug buprenorphine-naloxone (Zubsolv), drugmaker Orexo U.S. announced. (Source: MedPage Today Psychiatry)
FDA OKs New Formula for Addiction Drug
Previous post: Tox on the Web: the resurgence of heroin abuse, and more
Next post: Jennifer Serrentino, M.D. Recently Launches a Blog Post Discussing the…
